Jefferies Group Increases Kadmon (KDMN) Price Target to $16.00
Kadmon (NYSE:KDMN) had its price target increased by investment analysts at Jefferies Group to $16.00 in a report released on Tuesday, The Fly reports. The brokerage currently has a “buy” rating on the stock. Jefferies Group’s price target points to a potential upside of 230.58% from the company’s current price.
Several other equities research analysts also recently commented on KDMN. HC Wainwright reaffirmed a “buy” rating and set a $25.00 target price on shares of Kadmon in a report on Friday, November 17th. Zacks Investment Research raised Kadmon from a “sell” rating to a “hold” rating in a report on Tuesday, November 21st. Three analysts have rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $9.88.
Shares of Kadmon (NYSE KDMN) opened at $4.84 on Tuesday. Kadmon has a fifty-two week low of $2.05 and a fifty-two week high of $5.86. The company has a market capitalization of $376.70, a price-to-earnings ratio of -2.77 and a beta of 5.39.
TRADEMARK VIOLATION WARNING: “Jefferies Group Increases Kadmon (KDMN) Price Target to $16.00” was first reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this report on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The correct version of this report can be accessed at https://theolympiareport.com/2018/02/13/jefferies-group-increases-kadmon-kdmn-price-target-to-16-00.html.
Kadmon Company Profile
Kadmon Holdings, Inc is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases.
Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.